Molbio Diagnostics IPO Soars with 17% Listing Gain Anticipated as Demand Reaches Nearly 5x Subscription—Is It Time to Invest?
Molbio Diagnostics has showcased remarkable investor interest during its IPO process, notably achieving a subscription rate of 4.91 times on the final day of bidding. The IPO, which has a total issue size of Rs 939.70 crore, reflects strong demand particularly among non-institutional investors, whose segment was subscribed 10.43 times. Retail individual investors also demonstrated notable participation, subscribing 4.54 times their reserved portion. This robust demand is further underscored by a grey market premium (GMP) climbing to 17.10%, suggesting positive sentiment ahead of the anticipated listing.
The IPO comprises a fresh issue of shares valued at Rs 200 crore and an Offer for Sale (OFS) amounting to Rs 739.70 crore, enabling existing shareholders to liquidate their holdings. Among the sellers in the OFS are major entities such as Exxora Trading LLP and India Business Excellence Fund III, with the proceeds from their sales directly benefiting their balance sheets. The share price is set within the range of Rs 768 to Rs 807, with listing on the NSE and BSE expected on August 17, 2026. Proceeds from this issuance are intended to support infrastructure expansion and R&D development, critical for Molbio’s growth trajectory in the molecular diagnostics sector.
Financially, Molbio Diagnostics reported an impressive 42% year-on-year increase in total income for FY26, reaching Rs 1,455 crore, and an 18% rise in profit after tax, reflecting the company’s solid operational performance leading into this IPO. With strategic use of IPO proceeds aimed at enhancing R&D facilities and manufacturing capabilities, as well as sustaining general corporate purposes, investors can anticipate a focused growth strategy. Market analysts view the pricing of the IPO to be reasonable, with a price-to-earnings ratio below the average of its listed peers, making it an attractive proposition for investors looking for long-term growth in the diagnostic space.
Overall, given its established presence in the rapid diagnostics sector with innovative products such as the Truenat platform, and a well-structured plan for enhancing its infrastructure and R&D, Molbio Diagnostics presents a compelling case for investment. Analysts suggest that potential investors should closely consider the favorable industry trends and robust financial metrics when evaluating this IPO opportunity, particularly in light of the company’s intentions for substantial expenditure aimed at capacity expansion and improving operational efficiencies.
Source: The Economic Times
(Expert Note: This report was prepared by the Wealthova team.)